# ä»»åŠ¡äºŒï¼šæ•°æ®æå–æ¸…å•

**æ•°æ®æ¥æº**: å‚è€ƒç½‘ç«™ https://regulatorynav.com/regulatory-intelligence-hub  
**æˆªå›¾æ•°é‡**: 4å¼   
**æå–æ—¥æœŸ**: 2025-01-13

---

## ğŸ“Š ä»æˆªå›¾ä¸­æå–çš„æ–‡æ¡£æ•°æ®

### æˆªå›¾1 - æ–‡æ¡£ 1-4

#### æ–‡æ¡£1
- **æ ‡é¢˜**: Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development
- **æè¿°**: Draft guidance for industry on dosage optimization strategies for oncology therapeutic radiopharmaceuticals during clinical development
- **æ—¥æœŸ**: 2025/8/18 (ä»æˆªå›¾å¯è§ "08/18/25")
- **ç»„ç»‡**: Oncology Center of Excellence (ä»æˆªå›¾å¯è§ "Oncology Center of Excellence")
- **æ–‡ä»¶å¤§å°**: 362.51 KB (ä»æˆªå›¾å¯è§ "362.51 KB")
- **çŠ¶æ€**: Draft (ä»æˆªå›¾å¯è§ "Draft" æ ‡ç­¾)
- **ä¸»é¢˜æ ‡ç­¾**: ["Clinical - Medical", "Oncology"] (ä»æˆªå›¾å¯è§æ ‡ç­¾)
- **è¯„è®ºæœŸæˆªæ­¢**: 11/18/24 (ä»æˆªå›¾å¯è§ "Comment period closes: 11/18/24")
- **å›¾æ ‡**: "edit"

#### æ–‡æ¡£2
- **æ ‡é¢˜**: Approaches to Assessment of Covert Labeling in Oncology Clinical Trials
- **æè¿°**: Draft guidance for industry on methodological approaches to assess covert labeling in oncology clinical trials
- **æ—¥æœŸ**: 2025/4/8 (ä»æˆªå›¾å¯è§æ—¥æœŸ)
- **ç»„ç»‡**: Oncology Center of Excellence
- **æ–‡ä»¶å¤§å°**: çº¦ 500 KB (æˆªå›¾ä¸­ä¸å®Œå…¨æ¸…æ™°)
- **çŠ¶æ€**: Draft
- **ä¸»é¢˜æ ‡ç­¾**: ["Clinical - Medical", "Oncology", "Clinical Trials"]
- **è¯„è®ºæœŸæˆªæ­¢**: å¯èƒ½æœ‰ï¼Œä½†æˆªå›¾ä¸­ä¸æ¸…æ™°
- **å›¾æ ‡**: "edit"

#### æ–‡æ¡£3
- **æ ‡é¢˜**: Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions
- **æè¿°**: Final guidance for industry and FDA staff on marketing submission recommendations for a predetermined change control plan for AI/ML-enabled device software functions
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…å®Œæ•´æ—¥æœŸ
- **ç»„ç»‡**: Center for Devices and Radiological Health (CDRH)
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: Final (ä»æˆªå›¾å¯è§ "Final" æ ‡ç­¾)
- **ä¸»é¢˜æ ‡ç­¾**: ["AI/ML", "Software", "Premarket"]
- **å›¾æ ‡**: "file"

#### æ–‡æ¡£4
- **æ ‡é¢˜**: ICH Increases of Frequent and Infrequent Interim in Clinical Trials
- **æè¿°**: ä»æˆªå›¾çœ‹ä¸æ¸…å®Œæ•´æè¿°
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ç»„ç»‡**: å¯èƒ½æ˜¯ CDER
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ä¸»é¢˜æ ‡ç­¾**: ["ICH-Efficacy", "Clinical Trials"]
- **å›¾æ ‡**: å¾…ç¡®å®š

---

### æˆªå›¾2 - æ–‡æ¡£ 5-11

#### æ–‡æ¡£5
- **æ ‡é¢˜**: Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products
- **æè¿°**: Final guidance on how to conduct formal meetings between FDA and sponsors of biosimilar products
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…å®Œæ•´æ—¥æœŸ
- **ç»„ç»‡**: Center for Biologics Evaluation and Research (CBER)
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: Final
- **ä¸»é¢˜æ ‡ç­¾**: ["Biosimilars", "Administrative / Procedural"]
- **å›¾æ ‡**: "file"

#### æ–‡æ¡£6
- **æ ‡é¢˜**: Development of Cancer Drugs for Use in Neuro-Combination - Immunotherapy for Combination of the Indicated Drug (æ ‡é¢˜å¯èƒ½ä¸å®Œæ•´)
- **æè¿°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ç»„ç»‡**: å¯èƒ½æ˜¯ Oncology Center of Excellence
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ä¸»é¢˜æ ‡ç­¾**: ["Oncology", "Clinical - Medical"]
- **å›¾æ ‡**: å¾…ç¡®å®š

#### æ–‡æ¡£7
- **æ ‡é¢˜**: Stem Volume Treatment Drug Products and Metering Bulk Products for Parenteral Nutrition: Aluminum Content and Labeling Recommendations
- **æè¿°**: ä»æˆªå›¾çœ‹ä¸æ¸…å®Œæ•´æè¿°
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ç»„ç»‡**: å¯èƒ½æ˜¯ CDER
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ä¸»é¢˜æ ‡ç­¾**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **å›¾æ ‡**: å¾…ç¡®å®š

#### æ–‡æ¡£8
- **æ ‡é¢˜**: Pharmacokinetic Syndromes Circulating Drug and Biological Products for Treatment
- **æè¿°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ç»„ç»‡**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ä¸»é¢˜æ ‡ç­¾**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **å›¾æ ‡**: å¾…ç¡®å®š

#### æ–‡æ¡£9
- **æ ‡é¢˜**: Antimicrobial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases - Questions and Answers
- **æè¿°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ç»„ç»‡**: å¯èƒ½æ˜¯ CDER
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: Final
- **ä¸»é¢˜æ ‡ç­¾**: ["Clinical - Medical", "Infectious Diseases"]
- **å›¾æ ‡**: "file"

#### æ–‡æ¡£10
- **æ ‡é¢˜**: Can't Leave Diseases as Manifested by Cutaneous Migrans: Developing Drugs for Treatment (æ ‡é¢˜å¯èƒ½ä¸å‡†ç¡®)
- **æè¿°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ç»„ç»‡**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ä¸»é¢˜æ ‡ç­¾**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **å›¾æ ‡**: å¾…ç¡®å®š

#### æ–‡æ¡£11
- **æ ‡é¢˜**: Software as a Medical Device (SaMD): Clinical Evaluation
- **æè¿°**: Guidance on clinical evaluation requirements for software as a medical device
- **æ—¥æœŸ**: 2024/8/22 (å¯èƒ½ï¼ŒåŸºäºç°æœ‰æ•°æ®)
- **ç»„ç»‡**: Center for Devices and Radiological Health
- **æ–‡ä»¶å¤§å°**: 678.90 KB (å¯èƒ½ï¼ŒåŸºäºç°æœ‰æ•°æ®)
- **çŠ¶æ€**: Final
- **ä¸»é¢˜æ ‡ç­¾**: ["Software", "Digital Health", "Clinical - Medical"]
- **å›¾æ ‡**: "file"

---

### æˆªå›¾3 - æ–‡æ¡£ 12-19

#### æ–‡æ¡£12
- **æ ‡é¢˜**: Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions
- **æè¿°**: Draft guidance on cybersecurity considerations for medical device manufacturers
- **æ—¥æœŸ**: 2024/9/29 (å¯èƒ½ï¼ŒåŸºäºç°æœ‰æ•°æ®)
- **ç»„ç»‡**: Center for Devices and Radiological Health
- **æ–‡ä»¶å¤§å°**: 856.34 KB (å¯èƒ½ï¼ŒåŸºäºç°æœ‰æ•°æ®)
- **çŠ¶æ€**: Draft
- **ä¸»é¢˜æ ‡ç­¾**: ["Cybersecurity", "Quality Systems", "Premarket"]
- **å›¾æ ‡**: "edit"

#### æ–‡æ¡£13
- **æ ‡é¢˜**: Clinical Decision Support Software
- **æè¿°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ç»„ç»‡**: Center for Devices and Radiological Health
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: Final
- **ä¸»é¢˜æ ‡ç­¾**: ["Software", "Digital Health"]
- **å›¾æ ‡**: "file"

#### æ–‡æ¡£14
- **æ ‡é¢˜**: Quality System (QS) Regulation/Medical Device Good Manufacturing Practices
- **æè¿°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ç»„ç»‡**: Center for Devices and Radiological Health
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: Final
- **ä¸»é¢˜æ ‡ç­¾**: ["Quality Systems", "Manufacturing"]
- **å›¾æ ‡**: "file"

#### æ–‡æ¡£15
- **æ ‡é¢˜**: Design Controls Guidance for Medical Device Manufacturers
- **æè¿°**: Guidance on design control requirements for medical device development
- **æ—¥æœŸ**: 2024/6/12 (å¯èƒ½ï¼ŒåŸºäºç°æœ‰æ•°æ®)
- **ç»„ç»‡**: Center for Devices and Radiological Health
- **æ–‡ä»¶å¤§å°**: 567.89 KB (å¯èƒ½ï¼ŒåŸºäºç°æœ‰æ•°æ®)
- **çŠ¶æ€**: Final
- **ä¸»é¢˜æ ‡ç­¾**: ["Design Controls", "Premarket"]
- **å›¾æ ‡**: "file"

#### æ–‡æ¡£16
- **æ ‡é¢˜**: New Drug Application (NDA)
- **æè¿°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ç»„ç»‡**: Center for Drug Evaluation and Research
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: Final
- **ä¸»é¢˜æ ‡ç­¾**: ["NDA", "Product Development"]
- **å›¾æ ‡**: "file"

#### æ–‡æ¡£17
- **æ ‡é¢˜**: Abbreviated New Drug Application (ANDA)
- **æè¿°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ç»„ç»‡**: Center for Drug Evaluation and Research
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: Final
- **ä¸»é¢˜æ ‡ç­¾**: ["ANDA", "Generic Drugs"]
- **å›¾æ ‡**: "file"

#### æ–‡æ¡£18
- **æ ‡é¢˜**: Investigational New Drug (IND) Application
- **æè¿°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ç»„ç»‡**: Center for Drug Evaluation and Research
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: Final
- **ä¸»é¢˜æ ‡ç­¾**: ["IND", "Clinical Trials"]
- **å›¾æ ‡**: "file"

#### æ–‡æ¡£19
- **æ ‡é¢˜**: Biologics License Application (BLA) Process
- **æè¿°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ç»„ç»‡**: Center for Biologics Evaluation and Research
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: Final
- **ä¸»é¢˜æ ‡ç­¾**: ["BLA", "Product Development"]
- **å›¾æ ‡**: "file"

---

### æˆªå›¾4 - æ–‡æ¡£ 20

#### æ–‡æ¡£20
- **æ ‡é¢˜**: Biosimilar Product Development
- **æè¿°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **æ—¥æœŸ**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **ç»„ç»‡**: Center for Biologics Evaluation and Research
- **æ–‡ä»¶å¤§å°**: ä»æˆªå›¾çœ‹ä¸æ¸…
- **çŠ¶æ€**: Final
- **ä¸»é¢˜æ ‡ç­¾**: ["Biosimilars", "Product Development"]
- **å›¾æ ‡**: "file"

---

## âš ï¸ æ•°æ®æå–é—®é¢˜

### ä¸¥é‡é—®é¢˜
1. **æˆªå›¾åˆ†è¾¨ç‡ä¸è¶³**: å¾ˆå¤šæ–‡æ¡£çš„è¯¦ç»†ä¿¡æ¯ï¼ˆæ—¥æœŸã€æ–‡ä»¶å¤§å°ã€å®Œæ•´æ ‡é¢˜ï¼‰æ— æ³•æ¸…æ™°è¯»å–
2. **æ–‡æœ¬è¢«æˆªæ–­**: è®¸å¤šæ ‡é¢˜å’Œæè¿°è¢«æˆªæ–­ï¼Œæ— æ³•è·å–å®Œæ•´ä¿¡æ¯
3. **ç¼ºå¤±å…³é”®å­—æ®µ**: å¤§éƒ¨åˆ†æ–‡æ¡£ç¼ºå°‘ä»¥ä¸‹å…³é”®ä¿¡æ¯ï¼š
   - å‡†ç¡®çš„å‘å¸ƒæ—¥æœŸ
   - æ–‡ä»¶å¤§å°
   - å®Œæ•´çš„æè¿°
   - è¯„è®ºæœŸæˆªæ­¢æ—¥æœŸï¼ˆDraft æ–‡æ¡£ï¼‰

### å»ºè®®
**æ— æ³•ç»§ç»­æ‰§è¡Œä»»åŠ¡äºŒ**ï¼ŒåŸå› ï¼š
- æˆªå›¾è´¨é‡ä¸è¶³ä»¥æå–å®Œæ•´çš„æ–‡æ¡£æ•°æ®
- ç¼ºå°‘å¤ªå¤šå…³é”®å­—æ®µï¼ˆæ—¥æœŸã€æ–‡ä»¶å¤§å°ã€å®Œæ•´æ ‡é¢˜ç­‰ï¼‰
- æ— æ³•ä¿è¯æ•°æ®å‡†ç¡®æ€§

### è§£å†³æ–¹æ¡ˆ
è¯·æä¾›ä»¥ä¸‹ä»»ä¸€æ–¹å¼çš„æ•°æ®ï¼š
1. **æ›´é«˜åˆ†è¾¨ç‡çš„æˆªå›¾**ï¼šèƒ½å¤Ÿæ¸…æ™°çœ‹åˆ°æ¯ä¸ªæ–‡æ¡£çš„æ‰€æœ‰å­—æ®µ
2. **é€ä¸ªæ–‡æ¡£çš„è¯¦ç»†æˆªå›¾**ï¼šæ¯ä¸ªæ–‡æ¡£å•ç‹¬æˆªå›¾ï¼Œæ˜¾ç¤ºå®Œæ•´ä¿¡æ¯
3. **ç›´æ¥æä¾›æ•°æ®**ï¼šä»¥æ–‡æœ¬æˆ–è¡¨æ ¼å½¢å¼æä¾›20ä¸ªæ–‡æ¡£çš„å®Œæ•´æ•°æ®
4. **è®¿é—®æƒé™**ï¼šå¦‚æœå¯èƒ½ï¼Œæä¾›ç½‘ç«™è®¿é—®æƒé™ä»¥ä¾¿ç›´æ¥æå–æ•°æ®

---

**çŠ¶æ€**: âš ï¸ æš‚åœï¼Œç­‰å¾…æ›´æ¸…æ™°çš„æ•°æ®æº

